Alnylam Pharmaceuticals | ALNY - Market Capitalization

Stock Price
320.42
Daily Change
1.51 0.47%
Monthly
-3.69%
Yearly
31.16%
Q1 Forecast
303.95

Alnylam Pharmaceuticals reported $41.31B in Market Capitalization this March of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
Agios Pharmaceuticals USD 1.59B 745M Dec/2025
Alnylam Pharmaceuticals USD 52.54B 7.24B Dec/2025
Amgen USD 176.25B 24.32B Dec/2025
Arrowhead Research USD 9.02B 4.25B Dec/2025
BioCryst Pharmaceuticals USD 1.7B 40M Mar/2026
BioMarin Pharmaceutical USD 11.76B 348M Mar/2026
Incyte USD 19.39B 2.83B Dec/2025
Ionis Pharmaceuticals USD 12.81B 2.39B Dec/2025
Neurocrine Biosciences USD 14.14B 218M Dec/2025
Novartis USD 246.07B 11.81B Sep/2025
PTC Therapeutics USD 6.1B 1.22B Dec/2025
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Sanofi EUR 117.34B 2.45B Dec/2025
Sarepta Therapeutics USD 2.26B 238M Dec/2025
Takeda JPY 7.64T 774.9B Dec/2025
Tectonic Therapeutic USD 294M 77M Sep/2025
Ultragenyx Pharmaceutical USD 2.22B 680M Dec/2025
Vertex Pharmaceuticals USD 115.03B 14.61B Dec/2025
Xencor USD 1.09B 256M Dec/2025